Total amount: € 0,00
Morreale Bubella R.
Clinica Oculistica Università degli Studi di Palermo, Palermo, Italia
AIM: The purpose of this study was to assess the action of a single-dose ophthalmic solution containing sodium hyaluronate, amino acids and Echinacea purpurea extract in reducing the subjective and inflammatory symptoms in subjects with primary open-angle glaucoma and undergoing chronic therapy with prostaglandin analogues, and to verify the effects on the patients’ quality of life through the questionnaire NEI VFQ 25.
METHODS: Thirty patients suffering from primary open-angle glaucoma and undergoing therapy for at least five years with prostaglandin analogues were randomised to receive a treatment with a single-dose ophthalmic solution based on 0.15% sodium hyaluronate, Echinacea purpurea extract and amino acids (Collyrium A, 20 patients) or a treatment with single-dose ophthalmic solution of just 0.15% sodium hyaluronate (Collyrium B, 10 patients). All the subjects were analysed upon enrolment, after one month and after three months for: 1) assessment of the signs of ocular discomfort by means of OSDI test; 2) staining with fluorescein (grading according to Oxford scheme) and with lissamine green (grading according to Van Bijsterveld); 3) questionnaire on the quality of life NEI VFQ 25.
RESULTS: The subjects undergoing treatment with Collyrium A presented a reduction in the symptoms of ocular discomfort, with improvement also in the objective data and, in particular, in the tests with fluorescein and lissamine at the end of the three months of treatment. At the end of the observation period, almost all subjects (100% of men and 80% of women) presented values of NE1-VFQ indicative of a very good quality of life.
CONCLUSION: The use of a collyrium containing sodium hyaluronate, Echinacea purpurea extract and amino acids in subjects undergoing chronic therapy with prostaglandin analogues results in a considerable attenuation of some of the collateral effects deriving from this therapy. The improvement in the subjective and objective symptoms can contribute to improving the quality of life of patients suffering from chronic glaucoma.